Changes of several brain receptor complexes in the cerebral cortex of patients with Alzheimer disease: Probable new potential pharmaceutical targets

Amino Acids

Volumn 46, Issue 1, 2014, Pages 223-233

  Keihan Falsafi, Soheil ^a   Roßner, Steffen ^b   Ghafari, Maryam ^a   Groessl, Michael ^c   Morawski, Markus ^b   Gerner, Christopher ^c   Lubec, Gert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acetylcholine receptor; Alzheimer disease; Cerebral cortex; Dopamine receptor; Receptor complexes; Receptors

Indexed keywords

AGED; ALZHEIMER DISEASE; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; RECEPTORS, CELL SURFACE; SEX CHARACTERISTICS;

EID: 84895901632     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-013-1623-9     Document Type: Article

References (50)

1. Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558):408-414
2. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health Research Institute brain donation program: description and experience, 1987-2007. Cell Tissue Bank 9(3):229-245
3. Bernareggi A, Duenas Z, Reyes-Ruiz JM, Ruzzier F, Miledi R (2007) Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc Natl Acad Sci USA 104(8):2956-2960
4. Braak H, Rub U, Schultz C, Del Tredici K (2006) Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 9(3 Suppl):35-44
5. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61(1):39-61
6. Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH, Hof PR (2003) Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463(3):281-302
7. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30(5):211-219
8. Chang PK, Verbich D, McKinney RA (2012) AMPA receptors as drug targets in neurological disease: advantages, caveats, and future outlook. Eur J Neurosci 35(12):1908-1916
9. Chen P, Li X, Sun Y, Liu Z, Cao R, He Q, Wang M, Xiong J, Xie J, Wang X, Liang S (2006) Proteomic analysis of rat hippocampal plasma membrane: characterization of potential neuronal-specific plasma membrane proteins. J Neurochem 98(4):1126-1140
10. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351(1):56-67
11. D'Andrea MR, Nagele RG (2006) Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 12(6):677-684
12. de Bartolomeis A, Fiore G, Iasevoli F (2005) Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 11(27):3561-3594
13. DeCarli C (2003) Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2(1):15-21
14. Derkach VA, Oh MC, Guire ES, Soderling TR (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev 8(2):101-113
15. El-Ghundi M, O'Dowd BF, George SR (2001) Prolonged fear responses in mice lacking dopamine D1 receptor. Brain Res 892(1):86-93
16. Francis PT (2003) Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 18(Suppl 1):S15-S21
17. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66(2):137-147
18. Gao C, Sun X, Wolf ME (2006) Activation of D1 dopamine receptors increases surface expression of AMPA receptors and facilitates their synaptic incorporation in cultured hippocampal neurons. J Neurochem 98(5):1664-1677
19. Ghafari M, Falsafi SK, Hoeger H, Lubec G (2012a) Hippocampal levels of GluR1 and GluR2 complexes are modulated by training in the multiple T-maze in C57BL/6 J mice. Brain structure & function 217(2):353-362
20. Ghafari M, Hoger H, Keihan Falsafi S, Russo-Schlaff N, Pollak A, Lubec G (2012b) Mass spectrometrical identification of hippocampal NMDA receptor subunits NR1, NR2A-D and five novel phosphorylation sites on NR2A and NR2B. J Proteome Res 11(3):1891-1896
21. Ghidoni R, Paterlini A, Benussi L (2013) Translational proteomics in Alzheimer's disease and related disorders. Clin Biochem 46(6):480-486
22. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, McKeith IG, Perry RH, Aarsland D, Larsen JP, Sher E, Beattie R, Clementi F, Court JA (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 23(2):481-489
23. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 8:26
24. Groessl M, Luksch H, Rosen-Wolff A, Shevchenko A, Gentzel M (2012) Profiling of the human monocytic cell secretome by quantitative label-free mass spectrometry identifies stimulus-specific cytokines and proinflammatory proteins. Proteomics 12(18):2833-2842
25. Guarraci FA, Frohardt RJ, Falls WA, Kapp BS (2000) The effects of intra-amygdaloid infusions of a D2 dopamine receptor antagonist on Pavlovian fear conditioning. Behav Neurosci 114(3):647-651
26. Gurden H, Takita M, Jay TM (2000) Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J Neurosci 20(22):RC106
27. Hallett PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102(2):155-174
28. Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci 26(17):4690-4700
29. Kang SU, Fuchs K, Sieghart W, Lubec G (2008) Gel-based mass spectrometric analysis of recombinant GABA(A) receptor subunits representing strongly hydrophobic transmembrane proteins. J Proteome Res 7(8):3498-3506
30. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 103(3):702-707
31. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A (1998) Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792(2):331-334
32. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276(17):13541-13546
33. Kowall NW, Beal MF (1991) Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 29(2):162-167
34. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK (1999) Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73(4):1635-1640
35. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD) part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479-486
36. Ng J, Rashid AJ, So CH, O'Dowd BF, George SR (2010) Activation of calcium/calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. Neuroscience 165(2):535-541
37. Pandya AA, Yakel JL (2013) Activation of the alpha7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT(1a) receptor antagonist. Neuropharmacology 70:35-42
38. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985-1992
39. Revett TJ, Baker GB, Jhamandas J, Kar S (2012) Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 37(5):110190
40. Rinaldi A, Mandillo S, Oliverio A, Mele A (2007) D1 and D2 receptor antagonist injections in the prefrontal cortex selectively impair spatial learning in mice. Neuropsychopharmacology 32(2):309-319
41. Rusted JM, Newhouse PA, Levin ED (2000) Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 113(1-2):121-129
42. Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, Beach TG (2006) Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 63(12):1771-1776
43. Smith WB, Starck SR, Roberts RW, Schuman EM (2005) Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45(5):765-779
44. Sun X, Zhao Y, Wolf ME (2005) Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci 25(32):7342-7351
45. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51(3):474-486
46. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10(3):376-384
47. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275(8):5626-5632
48. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11(7):2551-2565
49. Willuhn I, Steiner H (2008) Motor-skill learning in a novel running-wheel task is dependent on D1 dopamine receptors in the striatum. Neuroscience 153(1):249-258
50. Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 97(1):1-13